CCDC28B Inhibitors
Chemical inhibitors of CCDC28B function by disrupting various intracellular signaling pathways that are essential for the protein's activity. MEK inhibitors such as SL327, PD98059, and U0126 specifically target the MAPK/ERK pathway, a critical route for the regulation of CCDC28B. These inhibitors prevent the phosphorylation and subsequent activation of ERK1/2 by inhibiting MEK1/2, leading to the functional inhibition of CCDC28B. The targeted action of these chemicals ensures that the activation of CCDC28B, which relies on the MAPK/ERK signaling cascade, is effectively impeded. Similarly, BIX 02189 serves to inhibit CCDC28B by selectively targeting MEK5, thereby preventing the activation of ERK5, another kinase that may participate in the regulation of CCDC28B.
In addition to the MAPK/ERK pathway, the PI3K/Akt pathway is another target for the functional inhibition of CCDC28B. LY294002 and Wortmannin are both PI3K inhibitors that block the phosphorylation and activation of Akt, a kinase downstream of PI3K. As a consequence, CCDC28B is functionally inhibited due to the disruption of signaling events that are necessary for its activity. The PI3K/Akt pathway's blockage by these inhibitors, therefore, directly affects the function of CCDC28B. Other kinase inhibitors, such as SB203580 and SP600125, inhibit p38 MAPK and JNK respectively, both of which are kinases that can influence CCDC28B activity through their signaling pathways. By inhibiting these kinases, the phosphorylation events crucial for CCDC28B's function are prevented. Additionally, PP2 and Dasatinib act as inhibitors of Src family tyrosine kinases, which participate in various signaling pathways that regulate CCDC28B, leading to its functional inhibition upon their blockade. Lastly, Rapamycin and PF-4708671 inhibit mTOR and p70S6 kinase, respectively, both of which are part of the mTOR signaling pathway that has downstream effects on the activity of CCDC28B. By targeting these kinases, the chemicals ensure that the functional aspects of CCDC28B linked to the mTOR pathway are effectively inhibited.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is a selective inhibitor of MEK1/2, enzymes upstream of ERK1/2 in the MAPK/ERK pathway, which CCDC28B is a part of. By inhibiting MEK1/2, SL327 prevents the phosphorylation and activation of ERK1/2, thereby inhibiting CCDC28B function that relies on ERK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor that impedes the MAPK/ERK pathway by blocking MEK activation. Since CCDC28B's function is contingent on this pathway, PD98059's inhibition of MEK results in decreased ERK activity, leading to the functional inhibition of CCDC28B. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that impedes the PI3K/Akt pathway. CCDC28B, involved in intracellular signaling, is functionally inhibited due to the resultant blockade of Akt phosphorylation and activation, which is essential for downstream signaling affecting CCDC28B. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, another PI3K inhibitor, functions similarly to LY294002 by preventing PI3K-mediated Akt activation. This disruption of the PI3K/Akt pathway leads to a lack of downstream signaling necessary for the functional activity of CCDC28B. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, blocking the activation of ERK1/2 within the MAPK/ERK pathway. The inhibition of this pathway results in the functional inhibition of CCDC28B, which requires active ERK1/2 for its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, a kinase that CCDC28B may rely on for its activation. Inhibition of p38 MAPK by SB203580 leads to decreased activity of CCDC28B due to the suppression of essential phosphorylation events. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, and by impeding JNK activity, it interferes with the JNK signaling pathway. CCDC28B, whose function is dependent on this pathway, is functionally inhibited due to the prevention of requisite phosphorylation events by SP600125. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and by inhibiting mTOR activity, it disrupts the mTOR signaling pathway. Since CCDC28B operates within cellular processes that are regulated by mTOR, the inhibition of mTOR by Rapamycin leads to the functional inhibition of CCDC28B. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases, which are involved in various signaling pathways that can regulate the function of CCDC28B. By inhibiting Src kinases, PP2 functionally inhibits CCDC28B by preventing its activation through these pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, which includes inhibition of Src family kinases. By blocking these kinases, Dasatinib leads to functional inhibition of CCDC28B as it may rely on Src-mediated signaling for its activity. | ||||||